Follow The Filings

Merck & Co., Inc.

Rahway, NJ 4 processed 13Fs on this site, 2025 Q3 to 2026 Q2

  • $526M
  • 13 holdings
  • 2026 Q2
  • +50.7% QoQ
  • Top 5 93.3%

Portfolio

2026 Q2, filed 8/7/2026, top 12 of 13 holdings

Top 5 93.3%, top 10 99.8%

  1. PSNL, Personalis 35.8%
  2. MRNA, Moderna 30.7%
  3. KYMR, Kymera Therapeutics 16.8%
  4. AKTS, Aktis Oncology 5.9%
  5. EIKN, Eikon Therapeutics 4.1%
  6. TRDA, Entrada Therapeutics 2.4%
  7. STRO, Sutro Biopharma 1.7%
  8. ALEC, Alector 1.4%
  9. Evaxion Biotech A/s 0.7%
  10. Viridian Therapeutics 0.3%
  11. Xilio Therapeutics 0.2%
  12. Tuhura Biosciences 0.0%
  13. Other 0.0%

AUM over time

2026 Q2 $526M +50.7% QoQ
2025 Q3: $228M 2025 Q3: $228M
Q3 2025
2025 Q4: $276M, +21.1% QoQ 2025 Q4: $276M, +21.1% QoQ
Q4
2026 Q1: $349M, +26.4% QoQ 2026 Q1: $349M, +26.4% QoQ
Q1 2026
2026 Q2: $526M, +50.7% QoQ 2026 Q2: $526M, +50.7% QoQ
Q2

Book

2025 Q3, filed 12 Nov, long equity only

Download CSV Download Excel
PSNL, Personalis 40.16% Hold 14,044,943 $6.52 $92M
MRNA, Moderna 26.15% Hold 2,308,190 $25.83 $60M
KYMR, Kymera Therapeutics 19.17% Hold 772,165 $56.60 $44M
ALEC, Alector 4.60% Hold 3,545,719 $2.96 $10M
TRDA, Entrada Therapeutics 4.43% Hold 1,739,768 $5.80 $10M
Evaxion Biotech A/s 2.00% Hold 1,214,126 $3.76 $4.6M
Sutro Biopharma 1.04% Hold 2,723,509 $0.8684 $2.4M
Viridian Therapeutics 0.88% Hold 93,414 $21.58 $2M
Lava Therapeutics 0.79% Hold 1,149,345 $1.56 $1.8M
Xilio Therapeutics 0.55% Hold 1,483,758 $0.8427 $1.3M
Carisma Therapeutics 0.18% Hold 1,473,240 $0.2740 $404K
Neuphoria Therapeutics 0.05% Hold 10,027 $11.79 $118K
Tuhura Biosciences 0.02% Hold 13,950 $2.48 $35K

* Reported price is value ÷ shares from the 13F as of period end, not a live market quote. Weight % is each long-equity position ÷ full 13F AUM, so rows may not sum to 100% when the filing includes options or other non-equity (excluded from this table). Click a column header to sort, or New, Hold, Add or Reduce to bring those moves to the top.

Filings history

4 periods, with AUM normalized

Newest 13Fs
Period Holds AUM QoQ Form Filed Filing ID
2026 Q2 13 $526M +50.7% 13F-HR 8/7/2026 000031015826000210
2026 Q1 14 $349M +26.4% 13F-HR 5/13/2026 000031015826000141
2025 Q4 12 $276M +21.1% 13F-HR 2/17/2026 000031015826000055
2025 Q3 13 $228M — 13F-HR 11/12/2025 000031015825000063

About

Merck & Co., Inc.

4 processed 13Fs on this site, 2025 Q3 to 2026 Q2

SEC filing name
Merck & Co., Inc.
Location
Rahway, NJ
All SEC filings
View on sec.gov

Further reading

As an Amazon Associate, FollowTheFilings earns from qualifying purchases.

  • The Essays of Warren Buffett, 8th Ed., Warren Buffett, Lawrence A. Cunningham View on Amazon
  • One Up On Wall Street (Lynch), Peter Lynch View on Amazon

More on the shelf